Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

Exelixis (EXEL) has performed well this year. Shares of the biotech company have gained 28.1% year to date against the industry’s decline of 3.5%. The stock has outperformed the sector and the S&P 500 Index in this timeframe.EXEL Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe company's upbeat performance can be attributed to its strong quarterly results, raised guidance, label expansion of Cabometyx (cabozantinib) and efforts to increase shareholders' returns.In March, the ...